Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Revenue (2019 - 2025)

C4 Therapeutics' Revenue history spans 7 years, with the latest figure at $11.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 112.79% year-over-year to $11.0 million; the TTM value through Dec 2025 reached $35.9 million, up 1.02%, while the annual FY2025 figure was $35.9 million, 1.02% up from the prior year.
  • Revenue reached $11.0 million in Q4 2025 per CCCC's latest filing, down from $11.2 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $20.1 million in Q4 2021 to a low of $2.7 million in Q2 2023.
  • Average Revenue over 5 years is $8.5 million, with a median of $7.5 million recorded in 2021.
  • Peak YoY movement for Revenue: crashed 85.79% in 2022, then surged 350.68% in 2024.
  • A 5-year view of Revenue shows it stood at $20.1 million in 2021, then plummeted by 85.79% to $2.9 million in 2022, then grew by 14.26% to $3.3 million in 2023, then skyrocketed by 58.75% to $5.2 million in 2024, then skyrocketed by 112.79% to $11.0 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Revenue are $11.0 million (Q4 2025), $11.2 million (Q3 2025), and $6.5 million (Q2 2025).